Skip to content

Septerna

US · SEPN #2886 by market cap Listed 2024
38.61 -0.59 -1.51%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 4.73 Expensive vs history 93rd percentile
5-year average 0.43 · #380 of 514 in Biotechnology
P/E ratio -32.77 In line with history 38th percentile
5-year average -30.51 · forward -13.45
P/S ratio 21.04 Cheap vs history 18th percentile
5-year average 383.77 · forward 29.40 · #220 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Septerna (SEPN) 1.84B -29.70 4.29 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value46.60 Economic moatNone UncertaintyHigh

Trading 20.7% below Morningstar's fair value estimate.

Fair value

Septerna Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 9% discount to our quantitative fair value estimate of $46.60 per share; however, caution is warranted due to this estimate's high uncertainty rating.

We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Septerna discussion 0 comments

Add a comment